Wyeth, Orchid Reach Deal In Effexor Patent Fight

Law360, New York (April 15, 2011, 1:35 PM EDT) -- Wyeth LLC on Thursday struck a licensing deal with generics maker Orchid Chemicals & Pharmaceuticals Ltd. over Effexor XR, resolving a patent dispute in New Jersey over the blockbuster antidepressant and anti-anxiety drug.

Under the settlement, Orchid agreed not to manufacture venlafaxine HCl extended-release capsules — the active ingredient in the drug — until the expiration of three relevant patents, except as permitted by a confidential licensing agreement.

Wyeth and Orchid submitted the deal to Judge Freda L. Wolfson of the U.S. District Court for the...
To view the full article, register now.